-
Posted by
Two Blokes Jun 18 -
Filed in
Stock
-
4 views
NanoViricides (NYSE-A:NNVC) said its experimental antiviral drug NV-387 could play a role in combating emerging threats from COVID-19 and bird flu, as new virus variants raise global health concerns. The company pointed to the rise of the COVID variant NB.1.8.1, or "Nimbus," which is spreading in the US and globally.
